Tracking Baker Brothers Portfolio: Q1 2026 Update
Edgewise Therapeutics Inc EWTX
$38.43
▼ -6.54%
($-2.69)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$41.11
Prev Close
$41.12
Day Range
$38.21 – $41.11
52W Range
$12.30 – $48.40
Market Cap
$4.13B
Beta
0.31
EPS (TTM)
$-1.66
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-03-26 |
| Shares Out. | 107,590,000 |
| Website | edgewisetx.com/ ↗ |
| Phone | 13026365401 |
| Employees | 154 |
| Net Income | -$49.0M |
| Free Cash Flow | -$149.0M |
| Total Assets | $518.5M |
| Total Liabilities | $25.3M |
| Equity | $493.2M |
About Edgewise Therapeutics Inc
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Edgewise Therapeutics Inc is a publicly traded company under the ticker symbol EWTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)